Lonafarnib is an orally bio-available farnesyltransferase inhibitor that prevents farnesylation of specific target proteins including Ras. In a multicenter study, 67 patients with advanced myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) were treated with a continuous oral dose of 200-300 mg of lonafarnib and were evaluated for hematologic, pathologic and pharmacodynamic response. The median age of patients was 70 years (range 44-86). There were 32 patients with MDS (RAEB-20 and RAEB-t-12) and 35 with CMML. Overall 16 (24%) of the patients responded with two patients achieving a complete remission and one a partial response. Responses were seen in 6/32 and 10/35 patients with MDS and CMML, respectively. Of the 19 patients who were platelet transfusiondependent prior to treatment, 5 (26%) became transfusion-free for a median duration of 185 days. A decrease in the farnesylation of the HDJ-2 protein measured in patient-derived cells was observed in the majority of patients during treatment with lonafarnib, but no clear correlation between changes in farnesylation and clinical effect could be made. Gastrointestinal toxicity was significant with 19% of patients discontinuing therapy due to diarrhea, nausea and/or anorexia. Lonafarnib has demonstrable activity in patients with advanced MDS and CMML.
Introduction
Myelodysplastic syndrome (MDS) encompasses a group of clonal hematologic disorders associated with progressive bone marrow failure and increased risk of evolution to acute myeloid leukemia (AML). 1 Current therapy consists of supportive transfusions, erythrogenic agents; erythropoietin and lenalidomide, hypomethylating agents and chemotherapy administered in low doses. [2] [3] [4] None of these approaches have resulted in long-term control or cure for the overwhelming majority of patients with MDS.
Emerging data have suggested that genetic alterations in multiple signal transduction pathways in the marrow of patients with MDS contribute to the progression of cytopenias and evolution to AML. 5 One such pathway, involving the Ras family of proteins, has been well studied. The role of Ras in the malignant process has been of particular interest because studies of Ras protein function and regulation have demonstrated an integral intermediary role in a number of signal transduction pathways controlling cell growth, proliferation and survival. 6 In patients with MDS, the frequency of activating Ras point mutations have been reported in up to 27% of patients. 7 The highest incidence of Ras mutations occur in patients with chronic myelomonocytic leukemia (CMML). 8 In addition, these studies suggest that patients with mutant Ras forms have an increased risk for progression to AML, indicating that acquisition of unrestrained Ras signaling may be an important step in disease progression in MDS. 9 Therapeutic strategies directed against Ras and Ras-mediated signal pathways may have a role in the treatment of MDS, CMML and AML. Many low molecular weight GTPases, including the mammalian Ras proteins, require post-translational modification to anchor to the cell surface and coordinate signals from activated receptors. The critical step in this process appears to be the addition of an isoprenoid group to the Cterminal portion of Ras, a process called prenylation, which is carried out by either one of two enzymes, farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase). 10 Farnesyltransferase inhibitors (FTIs) are a novel class of compounds that block this critical enzymatic step in the formation of active Ras. Lonafarnib (Sarasar, SCH66336) is an orally bio-available tricycyclic non-peptidomimetic FTI that inhibits the growth of a variety of tumors in vitro and in animal models of cancer. 11 Although the antitumor activity of lonafarnib as well as other FTIs, has been correlated with the degree of inhibition of farnesylation, it is still unclear as to which farnesylated proteins are the key targets of FTIs. Several proteins involved in signal transduction, other than Ras, also require farnesylation to be active 12 and clinical efficacy of FTIs has been observed in tumors without detectable Ras mutations. 13 Phase I trials of lonafarnib as a single agent and in combination with chemotherapy have been conducted in patients with solid tumors. 14, 15 In patients with advanced solid tumors, the maximally tolerated dose of lonafarnib by continuous daily administration was 200 mg twice daily. Dose limiting toxicities included gastrointestinal toxicities, diarrhea, nausea, vomiting and anorexia, as well as reversible renal dysfunction and confusion.
In patients with hematological malignancies, primarily acute leukemia and MDS, a phase I study of lonafarnib by continuous daily administration was conducted with doses ranging from 100 to 300 mg twice daily. 16 The maximally tolerated dose was 200 mg twice daily, the same as that seen in solid tumor patients, with a similar spectrum of toxicity. Based on these initial clinical experiences with lonafarnib, and the frequency and importance of Ras mutations in the progression of MDS to AML, a phase II evaluation was performed in patients with advanced MDS and CMML.
Materials and methods

Patient selection
From August 2001 to May 2003 patients with MDS were enrolled in a clinical trial conducted to evaluate the safety and efficacy of lonafarnib in patients with MDS and CMML. Patients with FAB subtypes refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-t) and patients with CMML were eligible for treatment as were patients with secondary MDS and those treated with prior therapy, including cytotoxic agents. Patients with refractory anemia and refractory anemia with ringed sideroblasts (RARS) and patients with 430% blasts within the blood or bone marrow were excluded. Patients required a serum creatinine p1.5 Â the upper limit of normal and a bilirubin p2 mg per 100 ml. An ECOG performance status of less than or equal to two was required and all patients signed informed consent according to institutional guidelines.
Treatment plan
All eligible patients enrolled in the study received lonafarnib at a dose of 200 mg p.o. bid. Four patients, treated on an earlier phase I trial, received 300 mg p.o. bid and are included in this analysis. Patients received supportive care with anti-emetics and anti-diarrheals as needed. Hematopoietic growth factors, erythropoietin and G-CSF/GM-CSF were not used during the study. Patients experiencing significant (4grade 2) toxicity had dose-interruptions until recovery from toxicity and then restarted at a reduced dose of 150 mg p.o. bid. Patients experiencing additional toxicity greater than grade 2 were taken off study.
Response criteria
Baseline bone marrow aspirations and biopsies were obtained on all patients to assess blast percentage and cytogenetics prior to therapy. Complete blood counts were obtained weekly or more frequently as clinically indicated. Marrow aspirates and/or biopsies were obtained 4 weeks from the start of therapy and then every 8 weeks while on study. Responses were graded according to established IWG 2000 guidelines for MDS. 17 Toxicity was graded using the NCI-Common toxicity scale (CTCAE version 2.0).
Pharmacokinetic and pharmacodynamic methods
Blood samples for determination of plasma lonafarnib concentrations were obtained in seven MDS/CMML patients. Samples were collected prior to drug administration (0 h) and at 1, 2, 4, 6 and 8 h post-dose on cycle 1 day 15. Additionally, pre-dose samples, defined as a sample collected 12 h after the previous evening dose and just prior to the morning dose on that day, were collected during cycle 1 on days 14, 15 and 16. Plasma was separated by centrifugation (4 1C, B3000 r.p.m. for 15 min), then divided into two aliquots, and was stored frozen at À70 1C until shipped to the analytical facility. Plasma lonafarnib concentrations were determined using a validated liquid chromatography with tandem mass spectrometric (LC-MS/MS) detection assay. The lower limit of quantitation was 5.00 ng/ml and linear concentration range was 5.00-2500 ng/ml. The assay precision (% coefficient of variation) and accuracy (% Bias) were o11 and o10%, respectively. For each patient, the maximum plasma concentration (C max ) and time of maximum plasma concentration (T max ) were the observed values. The area under the plasma concentration versus time curve (AUC) was calculated by the trapezoidal rule. The apparent total body clearance/F (F denotes the oral bio-availability fraction) was calculated as dose/AUC.
Inhibition of farnesyltransferase in patients was assessed by monitoring changes in the electrophoretic mobility of HDJ-2 protein from peripheral blood mononuclear cells (PBMCs). Unfarnesylated HDJ-2 migrates slower than farnesylated HDJ-2 and the amount of HDJ-2 in each band was determined by densitometry. A full description of the method can be found in Britten et al. 18 Briefly, PBMCs were isolated from each patient prior to treatment with lonafarnib and on day 15 after continuous bid dosing with lonafarnib. PBMCs were suspended in lysis buffer, centrifuged to remove insoluble material and the protein concentration determined. Ten microgram of the extracted protein were suspended in sample buffer with DTT and heated to 100 1C for 5 min. Samples were loaded on to 8% polyacrylamide gels and electrophoresed. The separated proteins were transferred to nitrocellulose and HDJ-2 protein was visualized by western blotting using the anti-HDJ-2 monoclonal antibody KA2A5.6 (Neomarkers, Thermo Fisher Scientific Inc., Fremont, CA, USA). HDJ-2 visualized from untreated or lonafarnib treated A549 cells provided a direct marker for farnesylated and unfarnesylated HDJ-2 and these samples were included on each gel. An increase in the unfarnesylated form of HDJ-2 from PBMC extracts of 10% or greater over baseline anytime post-dose were considered positive for a HDJ-2 shift. A total of seven patients had pre-treatment PBMC samples in which a band corresponding to unfarnesylated HDJ-2 was detected. A 10% or greater increase in the percentage of unfarnesylated HDJ-2 was required in subsequent samples from those patients to score positive for pharmacodynamic (PD) activity.
Results
Patient characteristics
Sixty-seven patients with MDS and CMML were enrolled into the study. There were 44 male subjects and 23 female subjects with an overall median age of 70 years (range 44-86) and 89% had an ECOG performance score of 0 or 1. French-AmericanBritish diagnostic categories of MDS included 20 patients with RAEB, 12 patients with RAEB-T and 35 patients with CMML. Using white blood cell count of greater than or less than 13 000 per 100 ml there were 11 patients with CMML sub-classified as 'myelodysplastic' (MDS-CMML) and 24 in the category of 'myeloproliferative' (MPD-CMML). Bone marrow karyotypes were available on 49 patients allowing for calculation of International Prognostic Scoring System (IPSS) risk category. Of these 49 patients, 24 were considered low or Int-1 and 25 were in the Int-2 or high-risk category. Twenty-three of the 67 total patients (34%) were red blood cell transfusion dependent prior to study entry and 19 (28%) were dependent on platelet transfusions pre-study. In addition to supportive transfusions, overall, 43 of the 67 patients had received single or multiple treatments specific for MDS prior to treatment with lonafarnib. Apart from supportive care with transfusions and hematopoietic growth factors, prior therapies for MDS included; single agent low-dose cytotoxic therapy (ara-c, azacitidine and hydroxyurea) in 23 pts, combination chemotherapy (anthracycline-ara-C) in 12 pts and other therapies (arsenic trioxide, thalidomide and investigational agents) in 11 pts.
Response to therapy
Overall 16 patients (24%) responded (complete response (CR), n ¼ 2, partial response (PR), n ¼ 1, HI, n ¼ 13) ( Table 1 ). Both CR's and the one PR were seen in patients with CMML. In addition, 13 patients met the IWG 2000 criteria for hematologic improvement, which included trilineage responses in two patients, bilineage in four patients and monolineage in eight patients. Platelet responses were seen in eight patients in total (MDS, n ¼ 2, CMML, n ¼ 6) and all were major responses. In these responders the median rise in the platelet count was 62 000/mm 3 (range 43-145 000/mm 3 ). Erythroid responses were seen in 10 patients in total and were major in 7. In responders, the median rise in Hgb was 3.1 g per 100 ml (range 1.0-6.5 g per 100 ml). Major neutrophil responses were seen in four patients. Among the 19 patients who were platelet transfusion dependent prior to treatment with lonafarnib, 5 became independent of transfusions with a median duration of response of 185 days (range 103-373 days). Twenty-three patients had received at least 2 units of red cells within 8 weeks of starting therapy with lonafarnib. Of these, 4 (17%) did not require red cell transfusions after therapy for a duration of 78, 140, 171 and 203 days, respectively. Improvements in bone marrow blast percentages were also observed on study. Of the patients with bone marrow blasts counts greater than 5% prior to therapy, a 50% reduction in blast percentage was seen in 18 of 39 (46%) patients with 13 of 39 (33%) patients achieving a blast count of o5%. In the MDS patient cohort, À3 of 12 with RAEB-t and 3 of 20 with RAEB responded. Within the MDS cohort, responses were observed in 1 of 3 patients with IPSS low/int-1, 5 of 19 with IPSS int-2/high and 0 of 10 with an undefined IPSS. Of the 35 pts with CMML, overall 10 (28%) responded. There were 4/11 responses in the MDS-CMML group and 6/24 in the MPD-CMML, which included the two patients achieving CR and the one patient who achieved a PR (Table 1) .
Toxicity
The side effects of lonafarnib are shown in Table 2 . The most common adverse effect seen was diarrhea, which occurred in 79% of patients and was Xgrade 3 in 25% of them. The onset of diarrhea was rapid, often within 1-2 days from the start of therapy, and was the major cause of drug discontinuation within the first month of therapy. Nausea/vomiting, anorexia and fatigue were also common, but were not severe in most cases. Despite dose interruptions and reduction to 150 mg twice daily, the use of anti-diarrheals, anti-emetics and appetite stimulating agents, 13 of the 67 patients (19%) discontinued therapy due to adverse events. Four of the 13 patients stopped treatment within 2-16 weeks due to diarrhea not controlled with medication. Apart from the non-hematologic toxicity, myelosuppression was not common.
Pharmacokinetic and pharmacodynamic results
Pharmacokinetic data were obtained from seven MDS/CMML patients (Table 3 ). There was a relatively flat concentration vs time profile over the 12-h dosing interval. The fluctuation between C max and pre-dose is minimal; mean pre-dose plasma lonafarnib concentrations were 44-84% of the corresponding C max values. Lonafarnib was slowly absorbed and eliminated following oral administration with food. Median T max values ranged from 4 to 6 hours. Total body clearance was 91-325 ml/min.
Pharmacodynamic marker activity
Samples for HDJ-2 analysis were received for 63 patients. The HDJ-2 shift in eight patients was not evaluable because either no HDJ-2 band was detected in the baseline sample or because no post-treatment samples were available. Therefore, a determination of PD activity was possible in a total of 55 patients in this study. Thirty-six of these 55 patients (65%) showed evidence of unfarnesylated HDJ-2 after treatment with lonafarnib. In only one of these 36 patients was unfarnesylated HDJ-2 detected in the pre-treatment sample. In this patient the post-treatment unfarnesylated HDJ-2 detected was 29.2% compared to the baseline of 17.1%. The amount of unfarnesylated HDJ-2 observed in PBMCs from these 36 patients ranged from 10.6 to 52.2%. 
Abbreviations: CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome.
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Sixteen patients in this study showed evidence of a hematological response after treatment with lonafarnib (Table 4) . Evidence of PD activity for lonafarnib was observed in 12 of these patients, including the 2 patients that experienced a CR. PD activity was not evaluable for one patient with a hematologic response because no HDJ-2 band was detected in the baseline sample. However, approximately 30% unfarnesylated HDJ-2 was observed in both post-treatment PBMC samples from this patient. PD activity was not found in the remaining three patients in whom hematologic response was observed. Thus, only 33-35% of the patients who had evidence of HDJ farnesylation achieved a hematological response and no significant correlation between clinical activity and PD response was observed (Figure 1 ). The inability of HDJ-2 shift changes in PBMCs to predict response to treatment was observed in both the MDS and CMML patient populations. The relationship between unfarnesylated HDJ-2 in PBMCs and pre-dose lonafarnib concentrations was evaluated in the relatively few patients in which pharmacokinetic and HDJ-2 shift data were evaluable. Although limited, these data showed that unfarnesylated HDJ-2 is consistently observed at the 200 mg BID dose level at exposures ranging from 819 to 4403 ng/ml.
Discussion
In this phase II trial lonafarnib, administered by a continuous daily dose, resulted in clinical responses in approximately onequarter of patients with advanced MDS and CMML. The majority of responses were characterized as hematologic improvement, with only two patients achieving a complete response. Hematologic improvements, however, were observed in all cell lineages. Clinically meaningful major increases in platelet counts were particularly encouraging, with consistent and durable responses seen in patients requiring transfusion support. In addition, several patients had significant reductions in red cell transfusions following therapy. Response rates were higher in patients with CMML compared to patients classified as MDS (28 vs 18%), and both complete responses and the single partial response were observed in the CMML patients, and in particular, the patients with proliferative CMML. Patients with CMML have been reported to have a higher frequency of Ras mutations compared to other leukemic/MDS patients, which might explain the higher activity seen in the CMML patients. However, none of the clinical studies with FTIs have, thus far, shown a relationship between clinical response and the presence of a Ras mutation.
Gastrointestinal toxicity associated with lonafarnib was common and was responsible for a relatively high proportion of patients discontinuing therapy, many within the first month of the trial. Diarrhea, which occurred often within 24 h of initiation of therapy, was the most frequent toxicity seen, and the most common reason for early discontinuation of therapy. Despite the liberal use of anti-diarrheals, it was ineffective in many patients who were predominantly older patients with MDS.
Tipifarnib, another non-peptidomimetic FTI, has been extensively studied in patients with MDS and AML. 19 In contrast to the gastro-intestinal side-effects seen with lonafarnib, phase I and II studies of tipifarnib in MDS have demonstrated that myelosuppression and central neurological effects were the primary dose-limiting toxicities. 20, 21 Despite the differences in toxicity profiles, a similar pattern of activity has been reported in MDS patients treated with tipifarnib. In the largest clinical experience to date, the overall response rate to tipifarnib was 32% including a complete response rate of 15% among 82 patients with advanced MDS. 22 Of interest is a similar observation that improvement in platelet counts in patients was the most common lineage of hematologic improvement suggesting that this represents a particular effect of the FTIs in MDS. Although the majority of MDS patients treated with FTIs have had advanced disease (IPSS Int 2/high), the effects seen on platelet counts warrant further evaluation in thrombocytopenic patients with less advanced disease.
The results of the current trial of lonafarnib, and the experiences with tipifarnib, have shown that the FTIs, a new class of anti-cancer drugs, have efficacy, albeit modest, as single agents in patients with MDS. Although the maximally tolerated doses have been defined for both agents, it is still unclear whether these doses and schedules are optimal. Dose-related effects on inhibition of farneslytransferase enzyme and blockade of farneslylation of surrogate proteins, such as HDJ-2 and Lamin A have been demonstrated, but these effects have not correlated with either the clinical activity of lonafarnib in this study, nor in the reported studies of tipifarnib in MDS and AML. Furthermore, in a recently reported trial by Kurzrock et al. 23 tipifarnib, administered at doses lower than the maximally tolerated dose, and in an intermittent rather than continuous manner, resulted in responses similar to that observed with higher doses with improved tolerance. Given the high rate of early treatment withdrawal with lonafarnib, an intermittent dose schedule of this agent might offer better tolerance, allowing more patients to continue on treatment, and consequently resulting in greater efficacy.
